A new conjugate vaccine against typhoid has been proven in trials in Oxford to be safe and effective in preventing the disease, and can be used to protect both adults and children.
A study published in The Lancet is the first clinical trial to show that immunisation with a new vaccine called Vi-TT is safe, well tolerated and will have significant impact on disease incidence in typhoid endemic areas that introduce the vaccine.
For the full story on Oxford Biomedical Research Centre website